996P Activity of OsimeRTInib in NSCLC with UNcommon EGFR Mutations: Retrospective observational multicenter study (ARTICUNO)

Abstract

In 10-20% of patients (pts) with EGFR mutated NSCLC, an assorted group of uncommon mutations can be detected. These mutations confer variable sensitivity to 1st and 2nd generation TKIs, overall resulting in lower therapeutic activity. Data of Osimertinib (Osi), a 3rd generation TKI, are limited and strongly warranted.